Results 161 to 170 of about 39,703 (285)

The Effect of Digoxin on the Intermediary Metabolism of the Heart as Measured by Glucose-C ¹⁴ Utilization in the Intact Dog

, 1960
Gerald A. Kien, Theodore R. Sherrod
openalex   +1 more source

Intravenous digoxin as a bioavailability standard [PDF]

, 1975
Roger G. Stoll, John G. Wagner, David J. Greenblatt, David W. Duhme, Jan Koch‐Weser, Thomas W. Smith, W. J. Tilstone, P. C. Reavey   +7 more
openalex   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. [PDF]

, 1977
Sylvia M. Dobbs, W I Kenyon, R. John Dobbs   +2 more
openalex   +1 more source

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered ...
Maria M. Posada, Karen B. Schneck, Bridget L. Morse, Luc R. A. Rougee, Lai San Tham, Jessica F. Rehmel, Brian Thompson, Stephen D. Stamatis, Stephen D. Hall, Gemma L. Dickinson   +9 more
wiley   +1 more source

Plasma and myocardial digoxin concentrations in patients on oral therapy.

, 1969
P. F. Binnion, L. M. Morgan, Helen Stevenson, Evan Fletcher   +3 more
openalex   +1 more source

Effect of exchange transfusions on plasma digoxin levels. [PDF]

, 1972
D J Coltart, Doris W. Watson, M. R. Howard   +2 more
openalex   +1 more source

Digoxin revisited [PDF]

QJM, 1998
F L, Li-Saw-Hee, G Y, Lip
openaire   +2 more sources

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R. Raber, Maria Lavinea Novis de Figueiredo, Manthena V. S. Varma   +6 more
wiley   +1 more source

Plasma digoxin concentrations and digoxin toxicity in hospital patients. [PDF]

, 1971
D.C. Evered, C.W. Chapman
openalex   +1 more source